Last reviewed · How we verify
Institut Kassab d'Orthopédie — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| tranexamic acid (Exacyl®) | tranexamic acid (Exacyl®) | phase 3 | Antifibrinolytic | Lysine receptor on plasminogen | Oncology, Surgery |
Therapeutic area mix
- Oncology, Surgery · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Bayer · 1 shared drug class
- German Heart Center · 1 shared drug class
- Miller Orthopedic Specialists · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Institut Kassab d'Orthopédie:
- Institut Kassab d'Orthopédie pipeline updates — RSS
- Institut Kassab d'Orthopédie pipeline updates — Atom
- Institut Kassab d'Orthopédie pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Institut Kassab d'Orthopédie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-kassab-d-orthop-die. Accessed 2026-05-16.